Mushroomβ-glucan and polyphenol formulations as natural immunity boosters and balancers:nature of the application

Mushrooms are experiencing a kind of renaissance as a part of the contemporary human diet.These valuable organisms are more than food,they fit in perfectly as a novel market group known as nutra-mycoceuticals.Immune-balancing mushroom dietary fibers and secondary metabolites such as polyphenols are the main focus of the healthcare industry.Wellness and cosmetic companies are increasingly using mushroom extracts rich in these ingredients.This review considers the basic molecular immunomodulatory mechanisms of action of the most commonly used mushroom dietary fibers,β-glucans.The literature data on their bioavailability,metabolic transformations,preclinical and human clinical research,and safety are discussed.Immunomodulatory mechanisms of polyphenol ingredients are also considered.These molecules present great potential in the design of the new immunity balancer formulations according to their widespread structural diversity.Finally,we draw attention to the perspectives of modern trends in mushroom nutraceutical and cosmeceutical formulations to strengthen and balance immunity.

Surrounding Plants as Reliable Immune Boosters

Recently, due to the growth of environmental pollution and the increase in the resistance of microorganisms to artificially create chemical drugs, there has been an urgent need for a radical change in the direction of the medical preparations development, for changing chemicals to naturally produced ones based on herbal natural remedies. Since homeopathy is a branch of medicine that includes not only herbal preparations, but also chemical ingredients, our newly developed patent—although it belongs to the field of homeopathy—is its offshoot aimed solely at maintaining the body’s strength without harming it, increasing the survival of the body in a polluted environment removing toxins from the body by strengthening adaptive immune mechanisms. Thus, thyme, cumin, oregano, licorice, and other natural resources of the earth, which are the basis of our patent, successfully fight cold and diseases of the upper respiratory tract. The article presents a methodology for the development of a new herbal preparation, its dosage, and use as the main ingredient in a treatment course in infectious diseases.

Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults

Inducing durable and effective immunity against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)via vaccination is essential to combat the current pandemic of coronavirus disease 2019(COVID-19).It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades over time,which calls for an additional vaccination regime,as known as booster immunization,to restore immunity among previously vaccinated populations.Here we report a pilot open-label trial of a third dose of BBIBP-CorV,an inactivated SARS-CoV-2 vaccine(Vero cell),on 136 participants aged between 18 to 63 years.Safety and immunogenicity in terms of neutralizing antibody titers and cytokine/chemokine responses were analyzed as the main endpoint until day 28.While systemic reactogenicity was either absent or mild,SARS-CoV-2-specific neutralizing antibody titers rapidly arose in all participants within 4 weeks,surpassing the peak antibody titers elicited by the initial two-dose immunization regime.Broad increases of cellular immunity-associated cytokines and chemokines were also detected in the majority of participants after the third vaccination.Furthermore,in an exploratory study,a newly developed recombinant protein vaccine,NVSI-06-08(CHO Cells),was found to be safe and even more effective than BBIBP-CorV in eliciting humoral immune responses in BBIBP-CorV-primed individuals.Together,these results indicate that a third immunization schedule with either homologous or heterologous vaccine showed favorable safety profiles and restored potent SARS-CoV-2-specific immunity,providing support for further trials of booster vaccination in larger populations.